LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC).

Moreira, Carolina Aguiar / Ferreira, Carlos Eduardo Dos S / Madeira, Miguel / Silva, Barbara Campolina Carvalho / Maeda, Sergio Setsuo / Batista, Marcelo Cidade / Bandeira, Francisco / Borba, Victória Z Cochenski / Lazaretti-Castro, Marise

Archives of endocrinology and metabolism

2020 Volume 64, Issue 4, Page(s) 462–478

Abstract: Hypovitaminosis D is a common condition with a negative impact on health. This statement, prepared by experts from the Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Clinical Pathology/Laboratory Medicine, includes ... ...

Abstract	Hypovitaminosis D is a common condition with a negative impact on health. This statement, prepared by experts from the Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Clinical Pathology/Laboratory Medicine, includes methodological aspects and limitations of the measurement of 25-hydroxyvitamin D [25(OH)D] for identification of vitamin D status, and identifies individuals at increased risk for deficiency of this vitamin in whom 25(OH)D measurement is recommended. For the general population, 25(OH)D levels between 20 and 60 ng/mL are considered normal, while individuals with levels below 20 ng/mL are considered to be vitamin D deficient. This statement identifies potential benefits of maintaining 25(OH)D levels > 30 ng/mL in specific conditions, including patients aged > 65 years or pregnant, those with recurrent falls, fragility fractures, osteoporosis, secondary hyperparathyroidism, chronic kidney disease, or cancer, and individuals using drugs with the potential to affect the vitamin D metabolism. This statement also calls attention to the risk of vitamin D intoxication, a life-threatening condition that occurs at 25(OH)D levels above 100 ng/mL.
MeSH term(s)	Aged ; Brazil ; Humans ; Pathology, Clinical ; Reference Values ; Vitamin D/analogs & derivatives ; Vitamin D Deficiency
Chemical Substances	Vitamin D (1406-16-2) ; 25-hydroxyvitamin D (A288AR3C9H)
Language	English
Publishing date	2020-06-05
Publishing country	Brazil
Document type	Journal Article
ISSN	2359-4292
ISSN (online)	2359-4292
DOI	10.20945/2359-3997000000258
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Reference values of 25-hydroxyvitamin D revisited

Carolina Aguiar Moreira / Carlos Eduardo dos S Ferreira / Miguel Madeira / Barbara Campolina Carvalho Silva / Sergio Setsuo Maeda / Marcelo Cidade Batista / Francisco Bandeira / Victória Z. Cochenski Borba / Marise Lazaretti-Castro

Archives of Endocrinology and Metabolism, Vol 64, Iss 4, Pp 462-

a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC)

2020 Volume 478

Abstract: ABSTRACT Hypovitaminosis D is a common condition with a negative impact on health. This statement, prepared by experts from the Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Clinical Pathology/Laboratory Medicine, ... ...

Abstract	ABSTRACT Hypovitaminosis D is a common condition with a negative impact on health. This statement, prepared by experts from the Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Clinical Pathology/Laboratory Medicine, includes methodological aspects and limitations of the measurement of 25-hydroxyvitamin D [25(OH)D] for identification of vitamin D status, and identifies individuals at increased risk for deficiency of this vitamin in whom 25(OH)D measurement is recommended. For the general population, 25(OH)D levels between 20 and 60 ng/mL are considered normal, while individuals with levels below 20 ng/mL are considered to be vitamin D deficient. This statement identifies potential benefits of maintaining 25(OH)D levels > 30 ng/mL in specific conditions, including patients aged > 65 years or pregnant, those with recurrent falls, fragility fractures, osteoporosis, secondary hyperparathyroidism, chronic kidney disease, or cancer, and individuals using drugs with the potential to affect the vitamin D metabolism. This statement also calls attention to the risk of vitamin D intoxication, a life-threatening condition that occurs at 25(OH)D levels above 100 ng/mL
Keywords	Vitamin D ; 25-hydroxyvitamin D ; reference range ; vitamin D intoxication ; Medicine ; R ; Diseases of the endocrine glands. Clinical endocrinology ; RC648-665
Subject code	610
Language	English
Publishing date	2020-06-01T00:00:00Z
Publisher	Brazilian Society of Endocrinology and Metabolism
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The use of PTH in the treatment of osteoporosis.

Borba, Victória Z Cochenski / Mañas, Nádila Cecyn Pietszkowski

Arquivos brasileiros de endocrinologia e metabologia

2010 Volume 54, Issue 2, Page(s) 213–219

Abstract: Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties ... ...

Abstract	Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.
MeSH term(s)	Anabolic Agents/adverse effects ; Anabolic Agents/therapeutic use ; Biomarkers/metabolism ; Bone Density/drug effects ; Bone Density Conservation Agents/adverse effects ; Bone Density Conservation Agents/therapeutic use ; Bone Resorption/metabolism ; Humans ; Lumbar Vertebrae/drug effects ; Osteoporosis/drug therapy ; Parathyroid Hormone/adverse effects ; Parathyroid Hormone/therapeutic use ; Spinal Fractures/prevention & control ; Teriparatide/adverse effects ; Teriparatide/therapeutic use
Chemical Substances	Anabolic Agents ; Biomarkers ; Bone Density Conservation Agents ; Parathyroid Hormone ; Teriparatide (10T9CSU89I)
Language	English
Publishing date	2010-05-19
Publishing country	Brazil
Document type	Journal Article ; Review
ZDB-ID	603919-4
ISSN	1677-9487 ; 0004-2730
ISSN (online)	1677-9487
ISSN	0004-2730
DOI	10.1590/s0004-27302010000200018
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 264: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The use of PTH in the treatment of osteoporosis Uso do PTH no tratamento da osteoporose

Victória Z. Cochenski Borba / Nádila Cecyn Pietszkowski Mañas

Arquivos brasileiros de Endocrinologia e Metabologia, Vol 54, Iss 2, Pp 213-

2010 Volume 219

Abstract	Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis. As drogas anabólicas ampliaram recentemente as opções terapêuticas no tratamento da osteo-porose e influenciam em maior escala os processos relacionados com a formação óssea, que ocorrem antes do efeito na reabsorção. Essas drogas afetam um grande número de propriedades esqueléticas, além da densidade mineral óssea. A administração intermitente de PTH leva a um aumento do número e atividade dos osteoblastos, ocasionando aumento da massa óssea e melhora da arquitetura, tanto do osso trabecular quanto cortical. O paratormônio recombinante humano (hrPTH 1-84) e o peptídeo recombinante humano 1-34 (teriparatide) pertencem a esse grupo de agentes. O objetivo deste artigo é revisar as ações, os benefícios e os efeitos adversos do PTH, assim como sua ação nos marcadores bioquímicos do metabolismo ósseo, a terapia combinada com drogas antirreabsortivas, o impacto do uso dos antirreabsortivos antes do tratamento anabólico, o tratamento sequencial e o tratamento da osteoporose induzida por glicocorticoides.
Keywords	Osteoporose ; PTH ; teriparatida ; anabólico ; Osteoporosis ; teriparatide ; anabolic ; Diseases of the endocrine glands. Clinical endocrinology ; RC648-665 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Language	Portuguese
Publishing date	2010-03-01T00:00:00Z
Publisher	Sociedade Brasileira de Endocrinologia e Metabologia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Osteoporosis after transplantation.

Kulak, Carolina A Moreira / Borba, Victoria Z Cochenski / Kulak, Jaime / Custódio, Melani Ribeiro

Current osteoporosis reports

2011 Volume 10, Issue 1, Page(s) 48–55

Abstract: Transplantation is an established therapy for end-stage diseases of kidney, lung, liver, and heart among others. Osteoporosis and fragility fractures are serious complications of organ transplantation, particularly in the first post-transplant year. Many ...

Abstract	Transplantation is an established therapy for end-stage diseases of kidney, lung, liver, and heart among others. Osteoporosis and fragility fractures are serious complications of organ transplantation, particularly in the first post-transplant year. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. This review addresses the mechanisms of bone loss that occurs both in the early and late post-transplant periods, including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac, and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient are also discussed.
MeSH term(s)	Animals ; Bone Marrow Transplantation/adverse effects ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Heart Transplantation/adverse effects ; Humans ; Hyperparathyroidism, Secondary/complications ; Immunosuppressive Agents/administration & dosage ; Kidney Transplantation/adverse effects ; Liver Transplantation/adverse effects ; Lung Transplantation/adverse effects ; Organ Transplantation/adverse effects ; Osteoporosis/complications ; Osteoporosis/etiology ; Osteoporotic Fractures/etiology ; Tacrolimus/pharmacology ; Vitamin D Deficiency/etiology
Chemical Substances	Glucocorticoids ; Immunosuppressive Agents ; Tacrolimus (WM0HAQ4WNM)
Language	English
Publishing date	2011-12-14
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2186581-4
ISSN	1544-2241 ; 1544-1873
ISSN (online)	1544-2241
ISSN	1544-1873
DOI	10.1007/s11914-011-0083-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Post-transplantation osteoporosis.

Kulak, Carolina A Moreira / Borba, Victória Z Cochenski / Kulak Júnior, Jaime / Campos, Denise Jonhsson / Shane, Elizabeth

Arquivos brasileiros de endocrinologia e metabologia

2010 Volume 54, Issue 2, Page(s) 143–149

Abstract: Transplantation is an established therapy for many hematologic disorders as well as for end-stage diseases of the kidney, lung, liver, heart among others. Osteoporosis and a high incidence of fragility fractures have emerged as a complication of organ ... ...

Abstract	Transplantation is an established therapy for many hematologic disorders as well as for end-stage diseases of the kidney, lung, liver, heart among others. Osteoporosis and a high incidence of fragility fractures have emerged as a complication of organ transplantation. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. In addition, most patients have some form of bone disease prior to transplantation, which is usually related to adverse effects of end-stage organ failure on the skeleton. This chapter reviews the mechanisms of bone loss that occur both in the early and late post-transplant periods including the contribution of immunosuppressive agents as well as the specific features of bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient will also be addressed.
MeSH term(s)	Bone Density ; Bone Marrow Transplantation/adverse effects ; Bone Resorption/metabolism ; Humans ; Osteoporosis/etiology ; Osteoporosis/prevention & control
Language	English
Publishing date	2010-05-19
Publishing country	Brazil
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	603919-4
ISSN	1677-9487 ; 0004-2730
ISSN (online)	1677-9487
ISSN	0004-2730
DOI	10.1590/s0004-27302010000200009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 264: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Post-transplantation osteoporosis Osteoporose pós-transplante

Carolina A. Moreira Kulak / Victória Z. Cochenski Borba / Jaime Kulak Júnior / Denise Jonhsson Campos / Elizabeth Shane

Arquivos brasileiros de Endocrinologia e Metabologia, Vol 54, Iss 2, Pp 143-

2010 Volume 149

Abstract	Transplantation is an established therapy for many hematologic disorders as well as for end-stage diseases of the kidney, lung, liver, heart among others. Osteoporosis and a high incidence of fragility fractures have emerged as a complication of organ transplantation. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. In addition, most patients have some form of bone disease prior to transplantation, which is usually related to adverse effects of end-stage organ failure on the skeleton. This chapter reviews the mechanisms of bone loss that occur both in the early and late post-transplant periods including the contribution of immunosuppressive agents as well as the specific features of bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient will also be addressed. Transplante de órgãos ou medula óssea é uma terapia conhecida para muitas doenças hematológicas e para estágios finais de doenças renais, pulmonares, hepáticas, cardíacas, entre outras. A osteoporose e o aumento da prevalência de fraturas por fragilidade óssea têm se mostrado como uma complicação do transplante. Muitos fatores contribuem para a patogênese da osteoporose relacionada ao transplante. Além disso, a maioria dos pacientes apresenta doença óssea antes do transplante, a qual é secundária à doença grave de base. Este artigo revisa os mecanismos da perda óssea que ocorrem tanto na fase precoce quanto na fase tardia após o transplante, incluindo o uso das drogas imunossupressoras, como também os fatores específicos envolvidos na perda óssea relacionados ao transplante renal, pulmonar, hepático, cardíaco e de medula óssea. A prevenção e o tratamento da osteoporose após transplante também são abordados nesta revisão.
Keywords	Osteoporose secundária ; transplante ; drogas imunossupressoras ; perda óssea ; Secondary osteoporosis ; transplantation ; immunosuppressive agents ; bone loss ; Diseases of the endocrine glands. Clinical endocrinology ; RC648-665 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Language	Portuguese
Publishing date	2010-03-01T00:00:00Z
Publisher	Sociedade Brasileira de Endocrinologia e Metabologia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Níveis baixos de 25-hidroxivitamina D (25OHD) em pacientes com doença inflamatória intestinal e sua correlação com a densidade mineral óssea.

Souza, Hevelyn Noemberg de / Lora, Fabiana Lígia / Kulak, Carolina A Moreira / Mañas, Nádila Cecyn Pietszkowski / Amarante, Heda M B / Borba, Victória Z Cochenski

Arquivos brasileiros de endocrinologia e metabologia

2008 Volume 52, Issue 4, Page(s) 684–691

Abstract: Unlabelled: Patients with inflammatory bowel disease (IBD) are at risk of having vitamin D deficiency (25-OHD) and low bone mineral density (BMD).: Objectives: To measure 25OHD in a young group of IBD patients submitted to a clinical evaluation, ... ...

Title translation	Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density.
Abstract	Unlabelled: Patients with inflammatory bowel disease (IBD) are at risk of having vitamin D deficiency (25-OHD) and low bone mineral density (BMD). Objectives: To measure 25OHD in a young group of IBD patients submitted to a clinical evaluation, routine biochemistry and BMD measurement (lumbar spine and proximal femur). Results: 39 Crohn disease (CD) and 37 ulcerative colitis (UC) patients had lower serum levels of 25OHD compared to the control group (CD p = 0.003; UC p < 0.001), and 48.5% of the UC patients were 25OHD deficient. Lumbar spine BMD was lower in patients than controls (CD p = 0.001; UC p = 0.008). In CD patients, serum levels of 25OHD were significantly correlated with total femur (r = 0.391; p = 0.027) and femoral neck (r = 0.384; p = 0.03) BMD. Conclusion: It was found lower levels of 25OHD and BMD in young IBD patients compared to normal controls, suggesting an important role of 25OHD deficiency in the pathogenesis of the IBD bone disease.
MeSH term(s)	Adult ; Bone Density ; Case-Control Studies ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/complications ; Crohn Disease/blood ; Crohn Disease/complications ; Female ; Humans ; Male ; Vitamin D/analogs & derivatives ; Vitamin D/blood ; Vitamin D Deficiency/diagnosis ; Vitamin D Deficiency/etiology ; Vitamin D Deficiency/physiopathology
Chemical Substances	Vitamin D (1406-16-2) ; 25-hydroxyvitamin D (A288AR3C9H)
Language	Portuguese
Publishing date	2008-06-11
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	603919-4
ISSN	1677-9487 ; 0004-2730
ISSN (online)	1677-9487
ISSN	0004-2730
DOI	10.1590/s0004-27302008000400015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 264: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Níveis baixos de 25-hidroxivitamina D (25OHD) em pacientes com doença inflamatória intestinal e sua correlação com a densidade mineral óssea Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density

Hevelyn Noemberg de Souza / Fabiana Lígia Lora / Carolina A. Moreira Kulak / Nádila Cecyn Pietszkowski Mañas / Heda M. B. Amarante / Victória Z. Cochenski Borba

Arquivos brasileiros de Endocrinologia e Metabologia, Vol 52, Iss 4, Pp 684-

2008 Volume 691

Abstract: INTRODUÇÃO: Pacientes com doenças inflamatórias intestinais (DII) estão propensos a apresentar níveis baixos de vitamina D (25OHD) e densidade mineral óssea (DMO) diminuída. OBJETIVO: Verificar o nível de 25OHD em jovens com DII submetidos à avaliação ... ...

Abstract	INTRODUÇÃO: Pacientes com doenças inflamatórias intestinais (DII) estão propensos a apresentar níveis baixos de vitamina D (25OHD) e densidade mineral óssea (DMO) diminuída. OBJETIVO: Verificar o nível de 25OHD em jovens com DII submetidos à avaliação clínica, dosagens bioquímicas rotineiras e medida da DMO de coluna lombar e fêmur, comparando-os com controles saudáveis. RESULTADOS: 39 pacientes com doença de Crohn (DC) (p = 0, 003) e 37 com retocolite ulcerativa inespecífica (RCUI) (p < 0,001) apresentaram níveis mais baixos de 25OHD comparados aos controles, 48,5% dos pacientes com RCUI tinham deficiência de 25OHD. A DMO em coluna lombar foi mais baixa nos doentes (DC p = 0,001; RCUI p = 0,008). A 25OHD correlacionou-se significativamente com a DMO do fêmur total (r = 0,391; p = 0,027) e colo do fêmur (r = 0,384; p = 0,03) na DC. CONCLUSÃO: Foram encontrados níveis baixos de 25OHD e DMO em jovens com DII, sugerindo papel importante desta deficiência na patogênese da doença óssea desses pacientes. Patients with inflammatory bowel disease (IBD) are at risk of having vitamin D deficiency (25-OHD) and low bone mineral density (BMD). OBJECTIVES: To measure 25OHD in a young group of IBD patients submitted to a clinical evaluation, routine biochemistry and BMD measurement (lumbar spine and proximal femur). RESULTS: 39 Crohn disease (CD) and 37 ulcerative colitis (UC) patients had lower serum levels of 25OHD compared to the control group (CD p = 0,003; UC p < 0,001), and 48.5% of the UC patients were 25OHD deficient. Lumbar spine BMD was lower in patients than controls (CD p = 0,001; UC p = 0,008). In CD patients, serum levels of 25OHD were significantly correlated with total femur (r = 0,391; p = 0,027) and femoral neck (r = 0,384; p = 0,03) BMD. CONCLUSION: It was found lower levels of 25OHD and BMD in young IBD patients compared to normal controls, suggesting an important role of 25OHD deficiency in the pathogenesis of the IBD bone disease.
Keywords	Vitamina D ; Osteoporose ; Doença inflamatória intestinal ; Densidade mineral óssea ; Doença de Crohn ; Retocolite ulcerativa inespecífica ; Vitamin D ; Osteoporosis ; Bone mineral density ; Inflammatory bowel disease ; Crohn Disease ; Ulcerative colitis ; Diseases of the endocrine glands. Clinical endocrinology ; RC648-665 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Language	Portuguese
Publishing date	2008-06-01T00:00:00Z
Publisher	Sociedade Brasileira de Endocrinologia e Metabologia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED